García-Olmo D, Herreros D, De-La-Quintana P, Guadalajara H, Trébol J, Georgiev-Hristov T, García-Arranz M
Department of Surgery, La Paz University Hospital-IdiPAZ, 28046 Madrid, Spain.
Case Rep Med. 2010;2010:961758. doi: 10.1155/2010/961758. Epub 2010 Mar 7.
Therapeutic options for recto-vaginal fistula in the setting of Crohn's disease are limited and many data are available in the literature. The manuscript describes the history of a patient who has been the pioneer of our Clinical Trials in treating this disease in fistulizing Crohn's disease environment. We believe it is the first time that a patient with this disease has been treated by adipose-derived stem cells in allogeneic form. The conclusion of our study with Mary is that the use of mesenchymal stem cells derived from adipose tissue is secure, either in autologous or allogeneic form. Furthermore, we have proved that if we use multi-dose and multiple applications on a patient, it does not produce any adverse effect, which confirms us the safety of using these cells in patients at least in the fistulizing Crohn's disease environment.
克罗恩病背景下直肠阴道瘘的治疗选择有限，文献中有许多相关数据。该手稿描述了一名患者的病史，该患者是我们在瘘管型克罗恩病环境中治疗这种疾病的临床试验的先驱。我们认为这是首次使用异体形式的脂肪源性干细胞治疗该疾病患者。我们对玛丽的研究结论是，使用源自脂肪组织的间充质干细胞无论是自体形式还是异体形式都是安全的。此外，我们已经证明，如果对患者使用多剂量和多次应用，不会产生任何不良反应，这证实了我们在至少瘘管型克罗恩病环境中使用这些细胞对患者的安全性。
